Seagen (SGEN) 10-Q2020 Q1 Quarterly report

Filed: 30 Apr 20, 5:16pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. senior Avg

New words: absenteeism, accommodate, accrual, Acrotech, added, agent, agreeable, allotted, ASC, back, bad, began, belantamab, beneficiary, Biopharm, bladder, broader, cap, Center, certiorari, chain, childcare, Circuit, codified, conform, contend, Corden, declaration, declaratory, dedicate, deruxtecan, description, deteriorating, dispense, dispensed, dispute, disseminate, distancing, doubtful, drying, Eighteen, EMA, England, error, essential, Esteve, exacerbate, Excellence, expiry, familiar, feedback, FGFR, footprint, formal, format, fourth, Genitourinary, handle, heard, heightened, heightening, hematologic, hepatotoxicity, home, hour, Hovione, immunomodulatory, IND, index, ingredient, Journal, lab, lawfully, led, licensee, MAA, mafodotin, magistrate, maximize, Medicine, MIBC, mistake, moderate, navigate, neoadjuvant, OCE, operationalized, opportunistic, outbreak, pace, PADCEV, PADCEVTM, pandemic, partner, paused, permanently, phone, pilot, Plankstadt, prejudice, prepaid, pretreated, proactive, proteasome, publicly, quantity, question, Quimica, recession, reclassification, reclassified, relax, remanded, remote, remotely, removing, residual, resume, RSU, RTOR, rulemaking, sample, scale, school, screen, sequester, shift, Simplifying, Singapore, slowdown, slower, societal, spray, spread, stay, Sterling, suit, surgery, talent, transmission, TUKYSA, TUKYSATM, uncover, unemployment, unresectable, upheld, verification, video, virtual, virtually, visibility, wider, worsening, yield

Removed: abandoning, ACTR, advice, ALCANZA, allocated, angioimmunoblastic, answer, Balversa, Beleodaq, blinded, central, CHECKMATE, cisplatin, citing, Code, coincide, combine, comparative, consist, CSR, cytotoxic, deductible, depreciation, elimination, enact, equivalent, excise, expired, fatigue, flat, Folotyn, forma, formed, forthcoming, funded, Herceptin, hinder, indemnification, initiation, Istodax, Kadcyla, Keytruda, leadership, linking, location, marginal, modifying, Nerlynx, offshore, Opdivo, penetration, Perjeta, PFS, Poteligeo, prepare, pro, rare, ratified, regimen, regulated, repatriated, resolution, restate, resubmit, retained, retroactive, secondary, Society, stated, taxation, threshold, tiered, top, Tykerb, undermine, Unum, varied

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated SGEN transcripts

SGEN similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

SEATTLE GENETICS, INC.

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Seattle Genetics, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Clay B. Siegall, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:


1.	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and


2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



By:	/s/ Clay B. Siegall
	Clay B. Siegall
	Chief Executive Officer
	(Principal Executive Officer)

Date:	April 30, 2020

This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Seattle Genetics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.